Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024 at 07:20 AM EST
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China) for AVZO-021 to Avenzo Therapeutics.
